| pubmed-article:11051263 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0104998 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0919437 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C1705431 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0444498 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C1517476 | lld:lifeskim |
| pubmed-article:11051263 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:11051263 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:11051263 | pubmed:dateCreated | 2001-1-29 | lld:pubmed |
| pubmed-article:11051263 | pubmed:abstractText | We have documented previously that adenovirus-mediated interleukin 12 (IL-12) gene therapy is effective for orthotopic tumor control and suppression of pre-established metastases in a preclinical prostate cancer model (Y. Nasu et al., Gene Ther., 6: 338-349, 1999). In this report, we directly compare the effectiveness of an adenovirus that expresses both IL-12 and the costimulatory molecule B7-1 (AdmIL12/B7) with one that expresses IL-12 alone (AdmIL-12) using the poorly immunogenic RM-9 orthotopic murine model of prostate cancer. We document AdmIL-12/B7-mediated secretion of IL-12 and increased surface expression of B7-1 in infected RM-9 tumor cells. A significant reduction in orthotopic tumor size and increased survival was demonstrated in mice treated with a single orthotopic injection of AdmIL-12/B7 compared with AdmIL-12 or controls. Six of 19 animals treated with AdmIL-12/B7 survived long term with apparent eradication of the primary tumor in contrast to one of 38 animals in the AdmIL-12-treated group. Orthotopic treatment of tumors with both vectors led to an infiltration of both CD4+ and CD8+ immunoreactive cells, with AdmIL-12/B7 treatment having a more prolonged infiltration of CD8+ cells. AdmIL-12/B7 was also more effective than AdmIL-12 or controls at suppression of pre-established metastases. We further developed a vaccine model based on s.c. injection of infected, irradiated RM-9 cells and found that both AdmIL-12 and AdmIL-12/B7 are effective at suppressing the development and growth of challenge orthotopic tumors using this protocol. | lld:pubmed |
| pubmed-article:11051263 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11051263 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11051263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11051263 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11051263 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11051263 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:SatoTT | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:WangJJ | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:LeeH MHM | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:NashDD | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:ShimuraSS | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:YanoOO | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:EbaraSS | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:AlbanoDD | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:ThompsonT CTC | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:TimmeT LTL | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:BangmaC HCH | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:HullG WGW | lld:pubmed |
| pubmed-article:11051263 | pubmed:author | pubmed-author:MccurdyM AMA | lld:pubmed |
| pubmed-article:11051263 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11051263 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:11051263 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11051263 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11051263 | pubmed:pagination | 4101-9 | lld:pubmed |
| pubmed-article:11051263 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:meshHeading | pubmed-meshheading:11051263... | lld:pubmed |
| pubmed-article:11051263 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11051263 | pubmed:articleTitle | Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. | lld:pubmed |
| pubmed-article:11051263 | pubmed:affiliation | Scott Department of Urology Baylor College of Medicine, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:11051263 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11051263 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11051263 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
